Current Report Filing (8-k)
09 Novembre 2022 - 01:26PM
Edgar (US Regulatory)
0001739174 false 0001739174 2022-11-09
2022-11-09 0001739174
PHGE:UnitsEachConsistingOfOneShareOfCommonStock0.0001ParValueAndOneWarrantEntitlingHolderToReceiveOneHalfShareOfCommonStockMember
2022-11-09 2022-11-09 0001739174
PHGE:SharesOfCommonStock0.0001ParValueMember 2022-11-09 2022-11-09
0001739174
PHGE:WarrantsEachExercisableForOnehalfOfShareOfCommonStock0.0001ParValueAtExercisePriceOf11.50PerShareMember
2022-11-09 2022-11-09 iso4217:USD xbrli:shares iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act
of 1934
Date of Report (Date of earliest event reported):
November 9, 2022
|
BiomX Inc. |
| (Exact
Name of Registrant as Specified in its Charter) |
|
Delaware |
|
001-38762 |
|
82-3364020 |
(State
or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(I.R.S.
Employer
Identification No.) |
22 Einstein St.,
Floor 4
Ness Ziona,
Israel |
|
7414003 |
| (Address
of Principal Executive Offices) |
|
(Zip
Code) |
Registrant’s telephone number, including area code: +972
723942377
|
n/a |
| (Former
name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425) |
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on
which registered |
|
Units, each consisting of one share of Common Stock, $0.0001 par
value, and one Warrant entitling the holder to receive one half
share of Common Stock |
|
PHGE.U |
|
NYSE American |
|
Shares of Common Stock, $0.0001 par value |
|
PHGE |
|
NYSE American |
|
Warrants, each exercisable for one-half of a share of common stock,
$0.0001 par value, at an exercise price of $11.50 per
share |
|
PHGE.WS |
|
NYSE American |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02 Results of Operations and Financial Condition.
On November 9, 2022, BiomX Inc., or the Company, issued a press
release announcing its financial results for the third quarter
ended September 30, 2022. A copy of the press release issued in
connection with the announcement is furnished pursuant to Item 2.02
as Exhibit 99.1 hereto.
Item 7.01 Regulation FD Disclosure.
The Company from time to time presents and/or distributes to the
investment community at various industry and other conferences
slide presentations to provide updates and summaries of its
business. On November 9, 2022, the Company posted an updated
corporate slide presentation in the “Investors” portion of its
website at www.biomx.com. A copy of the slide presentation is
furnished pursuant to Item 7.01 as Exhibit 99.2 hereto. The Company
undertakes no obligation to update, supplement or amend the
materials attached hereto as Exhibit 99.2.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
| |
BIOMX
INC. |
| |
|
|
| November
9, 2022 |
By: |
/s/
Jonathan Solomon |
| |
|
Name: |
Jonathan
Solomon |
| |
|
Title: |
Chief
Executive Officer |
2
BiomX (AMEX:PHGE)
Graphique Historique de l'Action
De Jan 2023 à Fév 2023
BiomX (AMEX:PHGE)
Graphique Historique de l'Action
De Fév 2022 à Fév 2023
